Joseph George1, Naren L Banik, Swapan K Ray. 1. Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, South Carolina 29209, USA.
Abstract
PURPOSE: The limitless invasive and proliferative capacities of tumor cells are associated with telomerase and expression of its catalytic component, human telomerase reverse transcriptase (hTERT). IFN-gamma modulates several cellular activities, including signaling pathways and cell cycle, through transcriptional regulation. EXPERIMENTAL DESIGN: Using a recombinant plasmid with hTERT siRNA cDNA, we downregulated hTERT during IFN-gamma treatment in human glioblastoma SNB-19 and LN-18 cell lines and examined whether such a combination could inhibit angiogenesis and tumor growth in nude mice. In vitro angiogenesis assay was done using coculture of tumor cells with human microvascular endothelial cells. In vivo angiogenesis assay was done using diffusion chambers under the dorsal skin of nude mice. In vivo imaging of intracerebral tumorigenesis and longitudinal solid tumor development studies were conducted in nude mice. RESULTS: In vitro and in vivo angiogenesis assays showed inhibition of capillary-like network formation of microvascular endothelial cells and neovascularization under dorsal skin of nude mice, respectively. We observed inhibition of intracerebral tumorigenesis and s.c. solid tumor formation in nude mice after treatment with combination of hTERT siRNA and IFN-gamma. Western blotting of solid tumor samples showed significant downregulation of the molecules that regulate cell invasion, angiogenesis, and tumor progression. CONCLUSIONS: Our study showed that the combination of hTERT siRNA and IFN-gamma effectively inhibited angiogenesis and tumor progression through the downregulation of molecules involved in these processes. Therefore, the combination of hTERT siRNA and IFN-gamma is a promising therapeutic strategy for controlling the growth of human glioblastoma.
PURPOSE: The limitless invasive and proliferative capacities of tumor cells are associated with telomerase and expression of its catalytic component, humantelomerase reverse transcriptase (hTERT). IFN-gamma modulates several cellular activities, including signaling pathways and cell cycle, through transcriptional regulation. EXPERIMENTAL DESIGN: Using a recombinant plasmid with hTERT siRNA cDNA, we downregulated hTERT during IFN-gamma treatment in humanglioblastoma SNB-19 and LN-18 cell lines and examined whether such a combination could inhibit angiogenesis and tumor growth in nude mice. In vitro angiogenesis assay was done using coculture of tumor cells with human microvascular endothelial cells. In vivo angiogenesis assay was done using diffusion chambers under the dorsal skin of nude mice. In vivo imaging of intracerebral tumorigenesis and longitudinal solid tumor development studies were conducted in nude mice. RESULTS: In vitro and in vivo angiogenesis assays showed inhibition of capillary-like network formation of microvascular endothelial cells and neovascularization under dorsal skin of nude mice, respectively. We observed inhibition of intracerebral tumorigenesis and s.c. solid tumor formation in nude mice after treatment with combination of hTERT siRNA and IFN-gamma. Western blotting of solid tumor samples showed significant downregulation of the molecules that regulate cell invasion, angiogenesis, and tumor progression. CONCLUSIONS: Our study showed that the combination of hTERT siRNA and IFN-gamma effectively inhibited angiogenesis and tumor progression through the downregulation of molecules involved in these processes. Therefore, the combination of hTERT siRNA and IFN-gamma is a promising therapeutic strategy for controlling the growth of humanglioblastoma.
Authors: Maria Laura Falchetti; Paolo Fiorenzo; Maria Patrizia Mongiardi; Giovanna Petrucci; Nicola Montano; Giulio Maira; Francesco Pierconti; Luigi Maria Larocca; Andrea Levi; Roberto Pallini Journal: Neurol Res Date: 2006-07 Impact factor: 2.448
Authors: Luo Wang; Qingyi Wei; Li-E Wang; Kenneth D Aldape; Yumei Cao; M Fatih Okcu; Kenneth R Hess; Randa El-Zein; Mark R Gilbert; Shiao Y Woo; Sujit S Prabhu; Greg N Fuller; Melissa L Bondy Journal: J Clin Oncol Date: 2006-04-01 Impact factor: 44.544
Authors: Phyllis R Wachsberger; Randy Burd; Nichol Marero; Constantine Daskalakis; Anderson Ryan; Peter McCue; Adam P Dicker Journal: Clin Cancer Res Date: 2005-01-15 Impact factor: 12.531
Authors: Ch Lavanya; M K Sibin; M M Srinivas Bharath; M Jeru Manoj; Manjunatha M Venkataswamy; Dhananjaya I Bhat; K V L Narasinga Rao; G K Chetan Journal: Cytotechnology Date: 2016-10-18 Impact factor: 2.058
Authors: Natalia Niewidok; Linda-Jacqueline Wack; Sarah Schiessl; Lavinia Stingl; Astrid Katzer; Bülent Polat; Vladimir L Sukhorukov; Michael Flentje; Cholpon S Djuzenova Journal: Transl Oncol Date: 2012-10-01 Impact factor: 4.243